This failure was foreseeable, as it will be next time.
Marketing evolves in markets--a disaster for science. Competition for jobs, grants and investors rewards deception of self and others. Innovators win by overselling
HT @HeatherEHeying https://www.technologyreview.com/the-download/611659/turns-out-crispr-editing-can-also-vandalize-genomes/?utm_campaign=social_button&utm_source=twitter&utm_medium=social&utm_content=2018-07-17 … via @techreview
-
You are off the mark here. CRISPR is an incredibly important, basically free, tool for inumerable research labs, enabling many discoveries. Competing methods orders of magnitude less efficient. The issue identified in the Nat. Biotech paper doesn't matter for many applications
My point isn't about its value, it is about the degree to which it has been oversold, which is substantial.
-
-
I think it would be difficult to overstate/oversell its impact in the research lab - where it is genuinely revolutionary. In terms of clinical applications, you may be right. But competing tech was stone-age by comparison. The off target issue is likely fixable - early days.
-
It is now fairly commonplace to make targeted (even single nucleotide) changes in germ-lines of mice, and some other animal species using CRISPR. The technical obstacles to doing this in humans are very likely surmountable. Challenging ethical questions follow.
End of conversation
New conversation -
-
-
Bailout, Bret! Embarrassing yourself. You over sold the oversell, and under sold the expert.pic.twitter.com/J8r42nwFj7
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
At least it was worked out early, rather than later... Eg. Theranos.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.